<DOC>
	<DOCNO>NCT02086929</DOCNO>
	<brief_summary>The study objective evaluate efficacy safety trazodone OAD v venlafaxine extend release ( venlafaxine XR ) 8-week treatment period patient major depressive disorder .</brief_summary>
	<brief_title>Trazodone Once Day Major Depression Disorder</brief_title>
	<detailed_description>This randomize , venlafaxine-controlled , double-blind , parallel design study consist Pre-Treatment Phase ( screen , wash-out ) double-blind Treatment Phase ( randomization trazodone OAD venlafaxine XR , treatment 8 week taper 1 3 week ) . During Pre-Treatment Phase , patient sign inform consent form undergo initial screening . Potential candidate instruct discontinue antidepressant prohibit medication ( wash-out ) period specific taper schedule ( base 5 elimination half-lives use medication ) . On last day Pre-Treatment Phase , patient evaluate final eligibility , qualify randomly allocate 1:1 proportion trazodone OAD 300 mg/day ( 1 week taper trazodone OAD 150 mg/day ) venlafaxine XR 75 mg/day daily . After 3 5 week treatment , subject evaluate response . For non respond patient dose increase ( increment 75 mg/day ) do till reach maximum 225 mg/day venlafaxine XR 450 mg/day trazodone OAD . Patients non respond treatment final visit study medication taper 1 3 week , accord maximum dose reach study . In order prevent relapse depression symptom , responder final visit may continue treatment . In case , unblinded third party Dispenser open treatment code prescribe medication take patient trial , accord formulation available market .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Trazodone</mesh_term>
	<criteria>men woman 1875 year age ( limit include ) limitation race ; outpatient ; major depressive disorder accord DSMIV criterion assess use MINI International Neuropsychiatric Interview ; 17item HAMD score &gt; 18 screen baseline visit decrease exceed 20 % screening baseline ; symptom depression least one month study entry ( screen visit ) ; legally capable give consent participate study , available sign date write informed consent prior inclusion study ; woman childbearing potential must agree start pregnancy signature inform consent 30 day last administration investigational product . participation another trial involve investigational drug past 60 day ; know hypersensitivity venlafaxine trazodone excipients ; use venlafaxine trazodone within previous six month ; acute , chronic , recurrent medical condition might affect/jeopardize study result ; significant liver disease , define active hepatitis elevate liver enzymes &gt; 3 time upper boundary normal range ; significant renal disease , define urea and/or creatinine &gt; 3 time upper boundary normal range myocardial infarction within 6 month prior start double blind treatment ; positive present history glaucoma ; history risk factor Torsade de Pointes , heart failure , cardiac arrhythmia , bradycardia , cardiac conduction abnormality , family history long QT syndrome , cardiac hypertrophy , cardiomyopathy , chronic cardiac insufficiency ; value electrolytes ( sodium , potassium , calcium , magnesium , chloride ) outside normal laboratory range judge clinically relevant Investigator ; concomitant treatment drug know QT prolongation , drug produce hypokalemia , diuretic ; QTcF value high 450 msec ECG perform screen ; history major depression resistant medical treatment ( previous failure respond two consecutive antidepressant different class use sufficient length time appropriate dos ) ; history seizure event single childhood febrile seizure ; history alcohol psychoactive substance abuse addiction ( except caffeine nicotine ) last year define DSMIV criterion ; positive urine drug screen CNSactive drug ( cocaine , opioids , amphetamine cannabinoids ) Visit 1 ( screen ) ; acute risk suicide ( HAMD , criterion 3 value &gt; 3 ) ; presence primary psychiatric disorder major depression ; history presence bipolar disorder , psychotic disorder , mental disorder due general medical condition ; pregnancy , lactation , female positive urine pregnancy test result Visit 1 ( Screening ) ; electroconvulsive therapy ( ECT ) within 30 day prior screen visit ; use antipsychotic drug within two month prior baseline visit ( Visit 2 ) ; use anxiolytic sedative hypnotic drug within seven day prior baseline ( Visit 2 ) study . Exception stable low dos benzodiazepine insomnia ( take patient two week Treatment Phase ) ; use psychotropic drug substance central nervous system effect within seven day prior baseline visit ( Visit 2 ) ; use nonpsychotropic drug psychotropic effect ( e.g . alphaadrenergic blocker ) within seven day prior baseline visit ( visit 2 ) , unless stable dose drug maintain least one month ( three month thyroid hormonal medication ) baseline visit ( visit 2 ) ; concomitant treatment CYP3A4 inhibitor ( e.g . ketoconazole , ritonavir , indinavir ) ; hyperthyroidism , even pharmacologically correct ; start discontinuation psychotherapy within 6 week prior screen ; clinically significant abnormality physical examination , vital sign , ECG , laboratory test screen visit ; high blood pressure ( supine systolic blood pressure &gt; 160 mmHg supine diastolic blood pressure &gt; 90 mmHg ) screen baseline , either untreated treatment antihypertensive inability comply protocol requirement , instruction studyrelated restriction ; e.g . uncooperative attitude , inability return studyvisits , improbability complete clinical study ; vulnerable subject ( e.g . person keep detention ) ; subject Investigator his/her deputy , first grade relative , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Trazodone</keyword>
	<keyword>Venlafaxine</keyword>
	<keyword>Major depressive disorder</keyword>
</DOC>